Back to Search
Start Over
Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
- Source :
-
Pediatric pulmonology [Pediatr Pulmonol] 2024 Apr; Vol. 59 (4), pp. 863-866. Date of Electronic Publication: 2024 Jan 05. - Publication Year :
- 2024
-
Abstract
- Nine people with cystic fibrosis (pwCF) were found to have isolated elevations in serum total bilirubin after starting elexacaftor/tezacaftor/ivacaftor (ETI) that were associated with Gilbert's Syndrome. In longitudinal examination, total bilirubin levels increased substantially after initiation of ETI without elevations in liver transaminases in those with this syndrome. Because elevated bilirubin levels in Gilbert's Syndrome are benign, ETI was able to be continued in these individuals. Genetic testing for this relatively common syndrome should be strongly considered for pwCF experiencing isolated hyperbilirubinemia after starting ETI, since appropriate diagnosis may help pwCF avoid unnecessary interruption in this therapy with significant health benefits in CF.<br /> (© 2024 Wiley Periodicals LLC.)
Details
- Language :
- English
- ISSN :
- 1099-0496
- Volume :
- 59
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Pediatric pulmonology
- Publication Type :
- Academic Journal
- Accession number :
- 38179880
- Full Text :
- https://doi.org/10.1002/ppul.26831